Your browser doesn't support javascript.
loading
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses.
Blagih, Julianna; Zani, Fabio; Chakravarty, Probir; Hennequart, Marc; Pilley, Steven; Hobor, Sebastijan; Hock, Andreas K; Walton, Josephine B; Morton, Jennifer P; Gronroos, Eva; Mason, Susan; Yang, Ming; McNeish, Iain; Swanton, Charles; Blyth, Karen; Vousden, Karen H.
Afiliación
  • Blagih J; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Zani F; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Chakravarty P; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Hennequart M; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Pilley S; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Hobor S; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Hock AK; Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK; Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca, Cambridge CB4 0WG, UK.
  • Walton JB; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.
  • Morton JP; Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.
  • Gronroos E; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Mason S; Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK.
  • Yang M; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • McNeish I; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK; Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
  • Swanton C; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK.
  • Blyth K; Cancer Research UK Beatson Institute, Switchback Road, Glasgow G61 1BD, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow G61 1QH, UK.
  • Vousden KH; The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: karen.vousden@crick.ac.uk.
Cell Rep ; 30(2): 481-496.e6, 2020 01 14.
Article en En | MEDLINE | ID: mdl-31940491
ABSTRACT
Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequences of p53 mutation have been studied extensively, the role of p53 in regulating the anti-tumor immune response is still poorly understood. Here, we show that loss of p53 in cancer cells modulates the tumor-immune landscape to circumvent immune destruction. Deletion of p53 promotes the recruitment and instruction of suppressive myeloid CD11b+ cells, in part through increased expression of CXCR3/CCR2-associated chemokines and macrophage colony-stimulating factor (M-CSF), and attenuates the CD4+ T helper 1 (Th1) and CD8+ T cell responses in vivo. p53-null tumors also show an accumulation of suppressive regulatory T (Treg) cells. Finally, we show that two key drivers of tumorigenesis, activation of KRAS and deletion of p53, cooperate to promote immune tolerance.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Linfocitos T Reguladores / Células Mieloides Idioma: En Revista: Cell Rep Año: 2020 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteína p53 Supresora de Tumor / Linfocitos T Reguladores / Células Mieloides Idioma: En Revista: Cell Rep Año: 2020 Tipo del documento: Article